Takata Tomoaki, Isomoto Hajime
Division of Gastroenterology and Nephrology, Faculty of Medicine, Tottori University, Japan.
Intern Med. 2025 Jul 24. doi: 10.2169/internalmedicine.5926-25.
Hyperuricemia is a common comorbidity of chronic kidney disease (CKD) and contributes to kidney dysfunction through mechanisms involving glomerular, tubular, and vascular injuries. Although hyperuricemia has traditionally been classified into overproduction and underexcretion types, recent evidence highlights the importance of intrarenal urate handling, particularly tubular reabsorption, in the pathogenesis of CKD. In this review, we revisit the physiology of renal urate transport and summarize the clinical evidence that links hyperuricemia to CKD progression. We also summarize the current evidence regarding urate-lowering therapies, mainly focusing on novel selective urate reabsorption inhibitors (SURIs) and kidney outcomes. Based on emerging data, we propose a refined classification of hyperuricemia in CKD that stratifies patients into glomerular under-filtration and tubular over-reabsorption subtypes using a novel index that integrates both glomerular filtration and tubular reabsorption. This new classification may better guide individualized treatment strategies for CKD patients with hyperuricemia.
高尿酸血症是慢性肾脏病(CKD)常见的合并症,通过涉及肾小球、肾小管和血管损伤的机制导致肾功能障碍。虽然传统上高尿酸血症被分为生成过多型和排泄减少型,但最近的证据强调了肾脏内尿酸处理,特别是肾小管重吸收,在CKD发病机制中的重要性。在本综述中,我们重新审视肾脏尿酸转运的生理学,并总结将高尿酸血症与CKD进展相关联的临床证据。我们还总结了关于降尿酸治疗的现有证据,主要关注新型选择性尿酸重吸收抑制剂(SURIs)和肾脏结局。基于新出现的数据,我们提出了一种CKD中高尿酸血症的细化分类,使用一种整合肾小球滤过和肾小管重吸收的新型指标将患者分为肾小球滤过不足和肾小管重吸收过多亚型。这种新的分类可能更好地指导CKD合并高尿酸血症患者的个体化治疗策略。